## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.5% below STRENGTH zone (4.0-10.0%); PEG 2.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($548.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. MASTERINVEST Kapitalanlage GmbH Makes New $1.15 Million Investment in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251215T120817 | Bullish | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH recently invested $1.15 million in Thermo Fisher Scientific Inc., acquiring 2,832 shares of the medical research company. This move follows similar investments by other institutional investors and hedge funds, showing strong institutional interest in TMO. Analysts have a "Moderate Buy" rating for the stock with an average target price of $614.60, and insider transactions show some selling activity balanced by a share repurchase program.

**2. National Bank of Canada FI Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251215T102458 | Somewhat-Bullish | Relevance: 100%
- National Bank of Canada FI significantly reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 41.6% in the second quarter, now holding 290,100 shares valued at approximately $117.6 million. This move comes as insiders have also been net sellers, disposing of about $86.5 million worth of shares. Despite institutional selling, Thermo Fisher Scientific reported strong quarterly earnings, beating analyst estimates, and announced a $5.0 billion share buyback program, with analysts maintaining a "Moderate Buy" consensus and an average price target of $614.60.

**3. B. Riley Wealth Advisors Inc. Purchases New Shares in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251215T082634 | Somewhat-Bullish | Relevance: 100%
- B. Riley Wealth Advisors Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by purchasing 5,647 shares valued at approximately $2.29 million during the second quarter. The medical research company recently reported strong quarterly earnings, beating analyst estimates, and authorized a $5.0 billion share repurchase program. Despite significant insider selling over the past three months, institutional investors continue to adjust their positions in TMO.

**4. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 37,958 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251213T100942 | Neutral | Relevance: 100%
- BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp has reduced its stake in Thermo Fisher Scientific Inc. by 22.3%, selling 37,958 shares and now holding 132,471 shares valued at approximately $53.71 million. This comes as Thermo Fisher exceeded quarterly expectations and provided strong FY2025 guidance, leading to an average analyst "Moderate Buy" rating and a $614.60 target price. The company also announced a $5.0 billion share repurchase program and a quarterly dividend of $0.43 per share.

**5. Thermo Fisher Scientific Inc. $TMO is BlueSpruce Investments LP's 9th Largest Position**
- Source: MarketBeat | 20251213T100850 | Bullish | Relevance: 100%
- BlueSpruce Investments LP has significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.2%, making it their 9th largest holding. Analysts maintain a "Moderate Buy" rating with an average price target of $614.60, following positive earnings reports and a share repurchase authorization. Insider selling has also been noted, but institutional ownership remains high at 89.23%.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.12 elevated, pricing in significant growth expectations. Forward P/E 23.2x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $215.0B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.12 |
| Forward P/E | 23.2 |
| Current P/E | 25.2 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.2% to -1.5% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-2.78), momentum weakening. RSI neutral at 50. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.51% (CS: 25) | Neutral |
| RSI_14 | 49.7 | Neutral |
| MACD Histogram | -2.78 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 1.013x | Above |
| vs SMA200 | 1.187x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $572.28
- **Stop Loss:** $548.10 (4.2% risk)
- **Target:** $596.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 41
- **Position Value:** $23,463.48
- **Portfolio %:** 23.46%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*